foxo4-dri 10mg senescence research FOXO4-DRI Vial 10mg — Stemcode

Reported benefits (per available research): Studied for restoring more youthful pulsatile GH and IGF-1 secretion in older adults, based on a small 1997 randomized, placebo-controlled human trial of a closely related GHRH(1-29) analog published in the Journal of Clinical Endocrinology & Metabolism May support gains in lean body mass in men specifically: that same 16-week trial found a statistically significant increase in lean body mass in men but not in women, alongside a significant increase in skin thickness (a marker of dermal collagen) in both sexes Proposed to support broader recovery and body-composition goals tied to growth-hormone-axis activity, though sermorelin-specific modern adult trial data remains thin, and much of the anti-aging and muscle-building framing used in commercial marketing outpaces the current clinical evidence base Known risks and side effects: Injection-site reactions (pain, swelling, or redness) are the most commonly reported adverse event associated with sermorelin therapy in manufacturer drug-labeling data Headache, flushing, dizziness, difficulty swallowing, hyperactivity, drowsiness, and hives have also been reported less commonly per that same labeling data

Adding it to the anti-aging toolkit complements the roles of DSIP and Epithalon

Furthermore, studies have examined these effects in fibroblast and keratinocyte cultures, endothelial and neuronal systems, and preclinical animal models related to wound repair and tissue response

Never shake the vial after reconstitution

It is an administrative standard rather than a measured expiry, and still the best number available